Header Logo

Connection

JASVINDER SINGH to Antirheumatic Agents

Back to Details
This is a "connection" page, showing publications JASVINDER SINGH has written about Antirheumatic Agents.
JASVINDER SINGH
Connection Strength
21.362
Antirheumatic Agents
  1. A narrative review of the comparative safety of disease-modifying anti-rheumatic drugs used for the treatment of rheumatoid arthritis. Expert Opin Drug Saf. 2024 Jun; 23(6):687-714.
    View in: PubMed
    Score: 0.777
  2. How to Use Janus Kinase Inhibitors in the Treatment of Rheumatoid Arthritis? A Clinical Assessment of Risks and Benefits. Curr Rheumatol Rep. 2023 12; 25(12):295-306.
    View in: PubMed
    Score: 0.753
  3. The Emerging Safety Profile of JAK Inhibitors in Rheumatic Diseases. BioDrugs. 2023 Sep; 37(5):625-635.
    View in: PubMed
    Score: 0.729
  4. Rituximab is associated with worse COVID-19 outcomes in patients with rheumatoid arthritis: A retrospective, nationally sampled cohort study from the U.S. National COVID Cohort Collaborative (N3C). Semin Arthritis Rheum. 2023 02; 58:152149.
    View in: PubMed
    Score: 0.702
  5. Treatment Guidelines in Rheumatoid Arthritis. Rheum Dis Clin North Am. 2022 08; 48(3):679-689.
    View in: PubMed
    Score: 0.681
  6. 2022 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty. Arthritis Rheumatol. 2022 09; 74(9):1464-1473.
    View in: PubMed
    Score: 0.680
  7. 2022 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty. Arthritis Care Res (Hoboken). 2022 09; 74(9):1399-1408.
    View in: PubMed
    Score: 0.679
  8. 2022 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty. J Arthroplasty. 2022 09; 37(9):1676-1683.
    View in: PubMed
    Score: 0.679
  9. Risks and Benefits of Janus Kinase Inhibitors in Rheumatoid Arthritis - Past, Present, and Future. N Engl J Med. 2022 01 27; 386(4):387-389.
    View in: PubMed
    Score: 0.661
  10. Pop a pill or give myself a shot? Patient perspectives of disease-modifying anti-rheumatic drug choice for rheumatoid arthritis. Joint Bone Spine. 2021 01; 88(1):105053.
    View in: PubMed
    Score: 0.594
  11. Important determinants of the patient choice between TNF- vs. non-TNF Biologic disease-modifying anti-rheumatic drugs (DMARDs) for active rheumatoid arthritis (RA). Joint Bone Spine. 2020 07; 87(4):307-313.
    View in: PubMed
    Score: 0.580
  12. Filgotinib, a JAK1 Inhibitor, for Treatment-Resistant Rheumatoid Arthritis. JAMA. 2019 07 23; 322(4):309-311.
    View in: PubMed
    Score: 0.555
  13. Cardiovascular Disease Risk in Older Adults and Elderly Patients with Rheumatoid Arthritis: What Role Can Disease-Modifying Antirheumatic Drugs Play in Cardiovascular Risk Reduction? Drugs Aging. 2019 06; 36(6):493-510.
    View in: PubMed
    Score: 0.550
  14. Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Rheumatol. 2019 01; 71(1):5-32.
    View in: PubMed
    Score: 0.531
  15. Tapering Janus kinase inhibitors in rheumatoid arthritis with low disease activity or remission: reality or dream? Ann Rheum Dis. 2019 02; 78(2):153-154.
    View in: PubMed
    Score: 0.526
  16. Allopurinol and the risk of incident peripheral arterial disease in the elderly: a US Medicare claims data study. Rheumatology (Oxford). 2018 03 01; 57(3):451-461.
    View in: PubMed
    Score: 0.504
  17. Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2017 05 08; 5:CD012657.
    View in: PubMed
    Score: 0.477
  18. Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2017 03 10; 3:CD012591.
    View in: PubMed
    Score: 0.471
  19. Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA). Cochrane Database Syst Rev. 2016 11 17; 11:CD012437.
    View in: PubMed
    Score: 0.461
  20. Infections With Biologics in Rheumatoid Arthritis and Related Conditions: a Scoping Review of Serious or Hospitalized Infections in Observational Studies. Curr Rheumatol Rep. 2016 10; 18(10):61.
    View in: PubMed
    Score: 0.457
  21. Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2016 May 13; (5):CD012183.
    View in: PubMed
    Score: 0.445
  22. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2016 Jan; 68(1):1-25.
    View in: PubMed
    Score: 0.429
  23. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet. 2015 Jul 18; 386(9990):258-65.
    View in: PubMed
    Score: 0.415
  24. Folic acid supplementation for rheumatoid arthritis patients on methotrexate: the good gets better. Cochrane Database Syst Rev. 2013 Jul 22; (7):ED000063.
    View in: PubMed
    Score: 0.366
  25. Use of biologics in a patient with rheumatoid arthritis refractory to methotrexate. CMAJ. 2013 Jun 11; 185(9):793-5.
    View in: PubMed
    Score: 0.357
  26. Harms of TNF inhibitors in rheumatic diseases: a focused review of the literature. Immunotherapy. 2013 Mar; 5(3):265-99.
    View in: PubMed
    Score: 0.357
  27. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012 May; 64(5):625-39.
    View in: PubMed
    Score: 0.337
  28. Summary of AHRQ's comparative effectiveness review of drug therapy for rheumatoid arthritis (RA) in adults--an update. J Manag Care Pharm. 2012 May; 18(4 Supp C):S1-18.
    View in: PubMed
    Score: 0.337
  29. Use of biologics in rheumatoid arthritis: current and emerging paradigms of care. Clin Ther. 2011 Jun; 33(6):679-707.
    View in: PubMed
    Score: 0.316
  30. Tocilizumab for rheumatoid arthritis: a Cochrane systematic review. J Rheumatol. 2011 Jan; 38(1):10-20.
    View in: PubMed
    Score: 0.302
  31. Tocilizumab for rheumatoid arthritis. Cochrane Database Syst Rev. 2010 Jul 07; (7):CD008331.
    View in: PubMed
    Score: 0.297
  32. Golimumab for rheumatoid arthritis: a systematic review. J Rheumatol. 2010 Jun; 37(6):1096-104.
    View in: PubMed
    Score: 0.293
  33. Golimumab for rheumatoid arthritis. Cochrane Database Syst Rev. 2010 Jan 20; (1):CD008341.
    View in: PubMed
    Score: 0.287
  34. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. CMAJ. 2009 Nov 24; 181(11):787-96.
    View in: PubMed
    Score: 0.283
  35. Abatacept for rheumatoid arthritis. Cochrane Database Syst Rev. 2009 Oct 07; (4):CD007277.
    View in: PubMed
    Score: 0.282
  36. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev. 2009 Oct 07; (4):CD007848.
    View in: PubMed
    Score: 0.282
  37. Anakinra for rheumatoid arthritis: a systematic review. J Rheumatol. 2009 Jun; 36(6):1118-25.
    View in: PubMed
    Score: 0.274
  38. Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials. Am J Manag Care. 2008 Apr; 14(4):234-54.
    View in: PubMed
    Score: 0.254
  39. Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials. Am J Manag Care. 2007 Dec; 13 Suppl 9:S237-51.
    View in: PubMed
    Score: 0.248
  40. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2021 07; 73(7):1108-1123.
    View in: PubMed
    Score: 0.158
  41. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2021 07; 73(7):924-939.
    View in: PubMed
    Score: 0.158
  42. OMERACT Filter 2.1: Elaboration of the Conceptual Framework for Outcome Measurement in Health Intervention Studies. J Rheumatol. 2019 08; 46(8):1021-1027.
    View in: PubMed
    Score: 0.135
  43. Instrument Selection Using the OMERACT Filter 2.1: The OMERACT Methodology. J Rheumatol. 2019 08; 46(8):1028-1035.
    View in: PubMed
    Score: 0.134
  44. Addressing Challenges in Developing a Core Domain Set in Adherence Interventions in Rheumatology: A Report from the OMERACT-Adherence Group. J Rheumatol. 2019 09; 46(9):1202-1206.
    View in: PubMed
    Score: 0.134
  45. Improving Benefit-harm Assessment of Therapies from the Patient Perspective: OMERACT Premeeting Toward Consensus on Core Sets for Randomized Controlled Trials. J Rheumatol. 2019 08; 46(8):1053-1058.
    View in: PubMed
    Score: 0.134
  46. Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Care Res (Hoboken). 2019 01; 71(1):2-29.
    View in: PubMed
    Score: 0.133
  47. Recommendations for the management of rheumatoid arthritis in the Eastern Mediterranean region: an adolopment of the 2015 American College of Rheumatology guidelines. Clin Rheumatol. 2018 Nov; 37(11):2947-2959.
    View in: PubMed
    Score: 0.130
  48. Outcome Measures in Rheumatology - Interventions for medication Adherence (OMERACT-Adherence) Core Domain Set for Trials of Interventions for Medication Adherence in Rheumatology: 5 Phase Study Protocol. Trials. 2018 Mar 27; 19(1):204.
    View in: PubMed
    Score: 0.127
  49. 2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty. Arthritis Care Res (Hoboken). 2017 08; 69(8):1111-1124.
    View in: PubMed
    Score: 0.120
  50. 2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty. Arthritis Rheumatol. 2017 08; 69(8):1538-1551.
    View in: PubMed
    Score: 0.120
  51. Clinical Practice Guidelines: Incorporating Input From a Patient Panel. Arthritis Care Res (Hoboken). 2017 08; 69(8):1125-1130.
    View in: PubMed
    Score: 0.120
  52. 2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty. J Arthroplasty. 2017 09; 32(9):2628-2638.
    View in: PubMed
    Score: 0.120
  53. Safety of Biologic and Nonbiologic Disease-modifying Antirheumatic Drug Therapy in Veterans with Rheumatoid Arthritis and Hepatitis C Virus Infection. J Rheumatol. 2017 05; 44(5):565-570.
    View in: PubMed
    Score: 0.118
  54. Defining the optimal biological monotherapy in rheumatoid arthritis: A systematic review and meta-analysis of randomised trials. Semin Arthritis Rheum. 2017 06; 46(6):699-708.
    View in: PubMed
    Score: 0.114
  55. Cervical cancer risk with the use of tumour necrosis factor inhibitors in rheumatoid arthritis: to worry or not to worry? Ann Rheum Dis. 2016 07; 75(7):1265-7.
    View in: PubMed
    Score: 0.110
  56. Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis. Ann Rheum Dis. 2016 Oct; 75(10):1813-8.
    View in: PubMed
    Score: 0.109
  57. When Patients Write the Guidelines: Patient Panel Recommendations for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2016 Jan; 68(1):26-35.
    View in: PubMed
    Score: 0.107
  58. Safety of biologic and nonbiologic disease-modifying antirheumatic drug therapy in veterans with rheumatoid arthritis and hepatitis B virus infection: a retrospective cohort study. Arthritis Res Ther. 2015 May 22; 17:136.
    View in: PubMed
    Score: 0.104
  59. Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014 Jul; 66(7):990-7.
    View in: PubMed
    Score: 0.098
  60. Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor. Clin Ther. 2012 Apr; 34(4):788-802.e3.
    View in: PubMed
    Score: 0.084
  61. Derivation and preliminary validation of an administrative claims-based algorithm for the effectiveness of medications for rheumatoid arthritis. Arthritis Res Ther. 2011; 13(5):R155.
    View in: PubMed
    Score: 0.081
  62. Biologicals for rheumatoid arthritis. BMJ. 2011 Jul 28; 343:d4027.
    View in: PubMed
    Score: 0.080
  63. Applying science in practice: the optimization of biological therapy in rheumatoid arthritis. Arthritis Res Ther. 2010; 12(6):220.
    View in: PubMed
    Score: 0.076
  64. Abatacept for rheumatoid arthritis: a Cochrane systematic review. J Rheumatol. 2010 Feb; 37(2):234-45.
    View in: PubMed
    Score: 0.072
  65. Newer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivity. Drugs. 2010; 70(2):121-45.
    View in: PubMed
    Score: 0.072
  66. Rituximab Treatment in Adult Patients With Idiopathic Inflammatory Myositis: A Systematic Review and Meta-analysis. J Clin Rheumatol. 2025 Jan 01; 31(1):33-39.
    View in: PubMed
    Score: 0.050
  67. Quantitative analysis of immunohistologic features of very early rheumatoid synovitis in disease modifying antirheumatic drug- and corticosteroid-na?ve patients. J Rheumatol. 2004 Jul; 31(7):1281-5.
    View in: PubMed
    Score: 0.049
  68. Leflunomide use during the first 33 months after food and drug administration approval: experience with a national cohort of 3,325 patients. Arthritis Rheum. 2003 Dec 15; 49(6):745-51.
    View in: PubMed
    Score: 0.047
  69. Trends in Joint Replacement Surgery in Patients with Rheumatoid Arthritis. J Rheumatol. 2018 02; 45(2):158-164.
    View in: PubMed
    Score: 0.031
  70. Development of the American College of Rheumatology's Rheumatoid Arthritis Electronic Clinical Quality Measures. Arthritis Care Res (Hoboken). 2016 11; 68(11):1579-1590.
    View in: PubMed
    Score: 0.029
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.